Potent peptidic fusion inhibitors of influenza virus-Reference-Cited by-同舟云学术

Potent peptidic fusion inhibitors of influenza virus

Published:2017-10-27 Issue:6362 Volume:358 Page:496-502
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Kadam Rameshwar U.¹^ORCID,Juraszek Jarek²^ORCID,Brandenburg Boerries²^ORCID,Buyck Christophe³^ORCID,Schepens Wim B. G.³^ORCID,Kesteleyn Bart⁴^ORCID,Stoops Bart³^ORCID,Vreeken Rob J.³^ORCID,Vermond Jan²^ORCID,Goutier Wouter²^ORCID,Tang Chan²^ORCID,Vogels Ronald²,Friesen Robert H. E.²,Goudsmit Jaap²⁵,van Dongen Maria J. P.²³^ORCID,Wilson Ian A.¹⁶^ORCID

Affiliation:

1. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.

2. Janssen Prevention Center, Leiden, Netherlands.

3. Discovery Sciences, Janssen Research & Development, Beerse, Belgium.

4. Janssen Infectious Diseases and Vaccines, Beerse, Belgium.

5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

6. The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA.

Abstract

Broadly reactive drugs for flu Drugs for influenza are limited. For those available, viral resistance is rife. Part of the problem is that the virus is constantly mutating. Kadam et al. tested the cell entry stage of the virus life cycle as a drug target (see the Perspective by Whitehead). Cell entry is mediated by the major surface glycoprotein hemagglutinin (HA). This stage can be blocked by broadly neutralizing antibodies binding to HA. The authors generated small cyclic peptides that bind to the same sites on HA as the antibodies and mimic their activity. The peptides are cheap and easy to synthesize, are nontoxic to mice, and prevented infection of cells by many types of influenza virus. Science , this issue p. 496 ; see also p. 450

Funder

National Institutes of Health

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference39 articles.

1. Structures of influenza A proteins and insights into antiviral drug targets

2. Antiviral agents active against influenza A viruses

3. Global Transmission of Oseltamivir-Resistant Influenza

4. Dual Resistance to Adamantanes and Oseltamivir Among Seasonal Influenza A(H1N1) Viruses: 2008–2010

5. Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review;Vaccine: X;2024-03

2. Viral Membrane Fusion: A Dance Between Proteins and Lipids;Annual Review of Virology;2023-09-29

3. Computational peptide engineering approach for selection of the new C05 antibody-driven peptide with potency to blocking influenza a virus attachment; from in silico to in vivo;Journal of Biomolecular Structure and Dynamics;2023-08-08

4. Bypassing the Need for Cell Permeabilization: Nanobody CDR3 Peptide Improves Binding on Living Bacteria;Bioconjugate Chemistry;2023-07-07

5. In Silico Design of an Oseltamivir Derivative with Increased Affinity against Wild‐Type and Mutant Variants of Neuraminidase and Hemagglutinin of Influenza A H1N1 Virus;Chemistry & Biodiversity;2023-06-28